ETIOLOGIC SIGNIFICANCE OF ARGININE VASOPRESSIN IN MOTION SICKNESS

PDF

Authors
  1. Cheung, B.S.K.
Corporate Authors
Defence and Civil Inst of Environmental Medicine, Downsview ONT (CAN)
Abstract
There is abundant evidence implicating the role of arginine vasopressin in motion sickness. The effects of AVP analogs on motion sickness were investigated in squirrel monkeys. Two specific V sub 1 antagonists (SK&F 100273 and SK&F 103561) and three mixed V sub 1/V sub 2 antagonists (SK&F 101926, SK&F 105494, and SK&F 104146-D) were tested on six highly susceptible monkeys. Intravenous injections of 200 ug of a V sub 1 antagonist abolished emesis in all six monkeys, and few prodromal symptoms remained (latency to emesis > 120 minutes, P < .001). Mixed V sub 1 and V sub 2 antagonists failed to abolish emesis in all monkeys. However, there was a slight increase in the latency of the first bout of emesis/retching with the mixed antagonists when compared with the baseline. The dose-response relationship and rate of onset of action of the V sub 1 antagonists (SK&F 100273) were explored. Latency to the first bout of emesis/retching increased to about twice that of the baseline when half of the effective antiemetic does was used. The efficacy demonstration by the specific V sub 1 antagonists indicates that V sub 1 receptors may modulate emesis.
Report Number
DCIEM-92-36 — Reprint
Date of publication
01 May 1992
Number of Pages
7
Reprinted from
J of Clinical Pharmacology, vol 34, no 6, 1994, p 664-670
DSTKIM No
95-03459
CANDIS No
152602
Format(s):
Document Image stored on Optical Disk;Hardcopy

Permanent link

Document 1 of 1

Date modified: